chromium(3+)/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
chromium(3+) — decreases tumour necrosis factor alpha concentration
Evidence strength: very limited.Findingreplicated ×1“Chromium reduced triglyceride (TG), atherogenic index of plasma (AIP), very-low-density lipoprotein (VLDL), insulin, homeostatic model assessment for insulin resistance (HOMA-IR), high-sensitivity C-reactive protein (hs-CRP), interleukin (IL) -6, tumor necrosis factor-alpha (TNF-α) and fetuin-A significantly compared to placebo group (p < 0.05).”
Quoted verbatim from A pilot study of the effects of chromium picolinate supplementation on serum fetuin-A, metabolic and inflammatory factors in patients with nonalcoholic fatty liver disease: A double-blind, placebo-controlled trial.. - Study
- RCT
- Dose
- chromium picolinate 400 mcg/day for 3 months
- Population
- 46 patients with nonalcoholic fatty liver disease
A pilot study of the effects of chromium picolinate supplementation on serum fetuin-A, metabolic and inflammatory factors in patients with nonalcoholic fatty liver disease: A double-blind, placebo-controlled trial.2021PMID:3304567510.1016/j.jtemb.2020.126659Permalink
To cite this finding: https://catalystproject.ai/e/01M5MEEC4DS2CDHK5BD7YMB1A0